// App-Quantinova.ai

6040.0 : A randomized multicenter phase II trial to evaluate the safety and efficacy of vaccination with folate receptor alpha (FRα) peptides admixed with GM-CSF as an adjuvant versus GM-CSF alone in patients with platinum-sensitive ovarian cancer (EOC).

Researchers

Presenter

  • Roisin Eilish O'Cearbhaill

Principal Investigators

  • Jason A. Konner

  • Matthew Stephen Block

  • James Potts

  • Gerald Garrett

  • Richard Kenney

  • Robert Michael Wenham

Medical Centers

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • Mayo Clinic, Rochester, MN

  • Veristat, Montreal, QC, Canada

  • Marker Therapeutics, Inc., Houston, TX

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • Folate Receptor 1

  • Granulocyte-macrophage-colony stimulating factor

Drug/Treatment

  • TPIV200

  • GM-CSF

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

Phase

  • NA

Study Id's

  • NCT02978222

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved